Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjdementia
VJNeurology
Logo
  • Home (current)
  • Diseases
    Parkinson's Disease
    Multiple Sclerosis and Related Disorders
    Headache
    Amyotrophic Lateral Sclerosis
    Epilepsy
    Sleep Disorders
    Stroke
    Neuromuscular Disorders
    Movement Disorders
    View all Diseases
  • Topics
    Biology
    Diagnostics
    Trial Updates
    Treatment
    Prevention
    Surgery
    Imaging
    Genetics
    COVID-19
    View all Topics
  • Conferences
    EHC 2022
    AES 2022
    WSC 2022
    ECTRIMS 2022
    EHDN 2022
    MDS 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Gennaro Pagano

Updates on α-synuclein as a biomarker in Parkinson’s disease 1:10
Updates on α-synuclein as a biomarker in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Development of novel trial outcomes in Parkinson’s disease 1:42
Development of novel trial outcomes in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Tackling sleep disturbances in Parkinson’s disease 1:33
Tackling sleep disturbances in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Prodromal Parkinson’s disease: identification & ethical issues 1:09
Prodromal Parkinson’s disease: identification & ethical issues
Gennaro Pagano • 17 Sep 2022
PADOVA trial: prasinezumab in early Parkinson’s disease 1:34
PADOVA trial: prasinezumab in early Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Exploratory delayed-start analysis of PASADENA in early-stage Parkinson’s disease 1:43
Exploratory delayed-start analysis of PASADENA in early-stage Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Alpha-synuclein as a therapeutic target for Parkinson’s disease 2:26
Alpha-synuclein as a therapeutic target for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Searching for therapeutic targets for Parkinson’s disease 1:32
Searching for therapeutic targets for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease 1:46
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Future prospects in Parkinson’s disease 1:00
Future prospects in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
PASADENA trial: prasinezumab in early Parkinson’s disease 1:24
PASADENA trial: prasinezumab in early Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease 1:29
Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Learnings from the PASADENA trial in Parkinson’s disease 1:49
Learnings from the PASADENA trial in Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Age at onset and Parkinson’s disease progression 1:10
Age at onset and Parkinson’s disease progression
Gennaro Pagano • 10 Mar 2021
The field of Parkinson’s disease research is expanding 1:24
The field of Parkinson’s disease research is expanding
Gennaro Pagano • 10 Mar 2021
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJNeurology via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJNeurology logo
The content of VJNeurology is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy